Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Arrowhead Pharmaceuticals (ARWR) EBITDA: 2010-2025

Historic EBITDA for Arrowhead Pharmaceuticals (ARWR) over the last 16 years, with Sep 2025 value amounting to $17.2 million.

  • Arrowhead Pharmaceuticals' EBITDA rose 110.27% to $17.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $31.8 million, marking a year-over-year increase of 105.29%. This contributed to the annual value of $31.8 million for FY2025, which is 105.29% up from last year.
  • According to the latest figures from Q3 2025, Arrowhead Pharmaceuticals' EBITDA is $17.2 million, which was up 109.68% from -$177.7 million recorded in Q2 2025.
  • Arrowhead Pharmaceuticals' 5-year EBITDA high stood at $368.1 million for Q1 2025, and its period low was -$177.7 million during Q2 2025.
  • Over the past 3 years, Arrowhead Pharmaceuticals' median EBITDA value was -$126.8 million (recorded in 2024), while the average stood at -$67.3 million.
  • As far as peak fluctuations go, Arrowhead Pharmaceuticals' EBITDA crashed by 366.45% in 2024, and later skyrocketed by 390.23% in 2025.
  • Quarterly analysis of 5 years shows Arrowhead Pharmaceuticals' EBITDA stood at -$62.9 million in 2021, then spiked by 33.35% to -$41.9 million in 2022, then tumbled by 218.15% to -$133.4 million in 2023, then tumbled by 31.80% to -$175.8 million in 2024, then surged by 110.27% to $17.2 million in 2025.
  • Its last three reported values are $17.2 million in Q3 2025, -$177.7 million for Q2 2025, and $368.1 million during Q1 2025.